Tradercommunity Clickoptions Forum

[Newsagent]

PR inside: CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer ...

(PR-inside.com) -- David Cory is an industry veteran, bringing more than 30 years of operational experience, in private and public, emerging-stage biotech and large pharma companies with an established track record of building and leading high performing operating teams and financing in the capital markets with over $1B+ raised and multiple company exits by acquisition

-- CID-103 is a potential best in class, anti-CD38 monoclonal antibody, currently dosing in a multi-center Phase 1/2 study in adults with chronic immune thrombocytopenia (ITP); IND submitted to support future clinical trials in adults with renal allograft antibody-mediated rejection (AMR)

BEIJING, CN / ACCESS Newswire / July ..

https://reports.pr-inside.com/casi-phar ... 121445.htm
Copyright PR-Inside.com 2025